A Case Report with Severe Thrombocytopenia Induced by Axitinib
Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma. Axitinib is ass...
Saved in:
Main Authors: | Ulkuhan I. Koksal, Janeiro Valle Goffin, Brian Lewis, Oliver A. Sartor, Elizaveta Belyaeva, Francisco Socola, Pedro C. Barata |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2020/7520783 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Life-Threatening Intrapulmonary Hemorrhage due to Vancomycin-Induced Thrombocytopenia: A Case Report
by: Haneen Abdalhadi, et al.
Published: (2020-01-01) -
Azithromycin-Induced Thrombocytopenia: A Rare Etiology of Drug-Induced Immune Thrombocytopenia
by: Muhammad Umer Butt, et al.
Published: (2019-01-01) -
Scrub Typhus Induced Thrombotic Thrombocytopenia: A Rare Case Report
by: Maharshi Patel, et al.
Published: (2025-01-01) -
Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
by: Norio Nonomura, et al.
Published: (2025-01-01) -
A “Catastrophic” Heparin-Induced Thrombocytopenia
by: D. Barcellona, et al.
Published: (2020-01-01)